On the feasibility of cardiac substructure sparing in magnetic resonance imaging guided stereotactic lung radiotherapy.


Journal

Medical physics
ISSN: 2473-4209
Titre abrégé: Med Phys
Pays: United States
ID NLM: 0425746

Informations de publication

Date de publication:
Jan 2023
Historique:
revised: 26 08 2022
received: 20 06 2022
accepted: 25 09 2022
pubmed: 11 10 2022
medline: 25 1 2023
entrez: 10 10 2022
Statut: ppublish

Résumé

Lung stereotactic body radiotherapy (SBRT) has proven an effective treatment for medically inoperable lung tumors, even for (ultra-)central tumors. Recently, there has been growing interest in radiation-induced cardiac toxicity in lung radiotherapy. More specifically, dose to cardiac (sub-)structures (CS) was found to correlate with survival after radiotherapy. Our goal is first, to investigate the percentage of patients who require CS sparing in an magnetic resonance imaging guided lung SBRT workflow, and second, to quantify how successful implementation of cardiac sparing would be. The patient cohort consists of 34 patients with stage II-IV lung cancer who were treated with SBRT between 2017 and 2020. A mid-position computed tomography (CT) image was used to create treatment plans for the 1.5 T Unity MR-linac (Elekta AB, Stockholm, Sweden) following clinical templates. Under guidance of a cardio-thoracic radiologist, 11 CS were contoured manually for each patient. Dose constraints for five CS were extracted from the literature. Patients were stratified according to their need for cardiac sparing depending on the CS dose in their non-CS constrained MR-linac treatment plans. Cardiac sparing treatment plans (CSPs) were then created and dosimetrically compared with their non-CS constrained treatment plan counterparts. CSPs complied with the departmental constraints and were considered successful when fulfilling all CS constraints, and partially successful if some CS constraints could be fulfilled. Predictors for the need for and feasibility of cardiac sparing were explored, specifically planning target volume (PTV) size, cranio-caudal (CC) distance, 3D distance, and in-field overlap volume histograms (iOVH). 47% of the patients (16 out of 34) were in need of cardiac sparing. A successful CSP could be created for 62.5% (10 out of 16) of these patients. Partially successful CSPs still complied with two to four CS constraints. No significant difference in dose to organs at risk (OARs) or targets was identified between CSPs and the corresponding non-CS constrained MR-linac plans. The need for cardiac sparing was found to correlate with distance in the CC direction between target and all of the individual CS (Mann-Whitney U-test p-values <10 We demonstrated that CS can be successfully spared in lung SBRT on the MR-linac for most of this patient cohort, without compromising doses to the tumor or to other OARs. CC distance between the target and CS can be used to predict the need for cardiac sparing. iOVHs, in combination with PTV size, can be used to predict if cardiac sparing will be successful for all constrained CS except the left ventricle.

Sections du résumé

BACKGROUND BACKGROUND
Lung stereotactic body radiotherapy (SBRT) has proven an effective treatment for medically inoperable lung tumors, even for (ultra-)central tumors. Recently, there has been growing interest in radiation-induced cardiac toxicity in lung radiotherapy. More specifically, dose to cardiac (sub-)structures (CS) was found to correlate with survival after radiotherapy.
PURPOSE OBJECTIVE
Our goal is first, to investigate the percentage of patients who require CS sparing in an magnetic resonance imaging guided lung SBRT workflow, and second, to quantify how successful implementation of cardiac sparing would be.
METHODS METHODS
The patient cohort consists of 34 patients with stage II-IV lung cancer who were treated with SBRT between 2017 and 2020. A mid-position computed tomography (CT) image was used to create treatment plans for the 1.5 T Unity MR-linac (Elekta AB, Stockholm, Sweden) following clinical templates. Under guidance of a cardio-thoracic radiologist, 11 CS were contoured manually for each patient. Dose constraints for five CS were extracted from the literature. Patients were stratified according to their need for cardiac sparing depending on the CS dose in their non-CS constrained MR-linac treatment plans. Cardiac sparing treatment plans (CSPs) were then created and dosimetrically compared with their non-CS constrained treatment plan counterparts. CSPs complied with the departmental constraints and were considered successful when fulfilling all CS constraints, and partially successful if some CS constraints could be fulfilled. Predictors for the need for and feasibility of cardiac sparing were explored, specifically planning target volume (PTV) size, cranio-caudal (CC) distance, 3D distance, and in-field overlap volume histograms (iOVH).
RESULTS RESULTS
47% of the patients (16 out of 34) were in need of cardiac sparing. A successful CSP could be created for 62.5% (10 out of 16) of these patients. Partially successful CSPs still complied with two to four CS constraints. No significant difference in dose to organs at risk (OARs) or targets was identified between CSPs and the corresponding non-CS constrained MR-linac plans. The need for cardiac sparing was found to correlate with distance in the CC direction between target and all of the individual CS (Mann-Whitney U-test p-values <10
CONCLUSION CONCLUSIONS
We demonstrated that CS can be successfully spared in lung SBRT on the MR-linac for most of this patient cohort, without compromising doses to the tumor or to other OARs. CC distance between the target and CS can be used to predict the need for cardiac sparing. iOVHs, in combination with PTV size, can be used to predict if cardiac sparing will be successful for all constrained CS except the left ventricle.

Identifiants

pubmed: 36210631
doi: 10.1002/mp.16028
pmc: PMC10092491
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

397-409

Subventions

Organisme : Nederlandse Organisatie voor Wetenschappelijk Onderzoek
ID : 17515

Informations de copyright

© 2022 The Authors. Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine.

Références

Cancers (Basel). 2022 Mar 09;14(6):
pubmed: 35326542
Acta Oncol. 2021 Aug;60(8):1061-1068
pubmed: 34191670
Phys Imaging Radiat Oncol. 2022 May 24;23:24-31
pubmed: 35923896
Radiat Oncol. 2016 Sep 06;11(1):115
pubmed: 27600665
Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1229-38
pubmed: 18313530
Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):313-21
pubmed: 24685448
Phys Imaging Radiat Oncol. 2021 Apr 16;18:34-40
pubmed: 34258405
Radiother Oncol. 2020 Nov;152:126-132
pubmed: 33058951
Med Phys. 2023 Jan;50(1):397-409
pubmed: 36210631
Radiother Oncol. 2014 Aug;112(2):221-6
pubmed: 25108808
Radiat Oncol. 2017 Feb 1;12(1):34
pubmed: 28143532
Int J Radiat Oncol Biol Phys. 2019 Jul 1;104(3):582-589
pubmed: 30630029
Radiother Oncol. 2012 Jan;102(1):38-44
pubmed: 21680036
Phys Med. 2017 Dec;44:139-149
pubmed: 28242140
JAMA Oncol. 2021 Feb 01;7(2):206-219
pubmed: 33331883
J Appl Clin Med Phys. 2021 Feb;22(2):203-210
pubmed: 33493385
Clin Lung Cancer. 2020 Mar;21(2):136-144.e1
pubmed: 31932217
Radiother Oncol. 2017 Nov;125(2):293-300
pubmed: 29050957
J Med Phys. 2018 Jul-Sep;43(3):147-154
pubmed: 30305771
Med Image Comput Comput Assist Interv. 2009;12(Pt 2):100-8
pubmed: 20426101
Semin Radiat Oncol. 2014 Jul;24(3):207-9
pubmed: 24931095
Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):933-941
pubmed: 30928360
Radiother Oncol. 2017 Oct;125(1):62-65
pubmed: 28939179
Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):590-8
pubmed: 18037579
Adv Radiat Oncol. 2021 Dec 24;7(3):100876
pubmed: 35243181
Phys Med Biol. 2022 Mar 09;67(6):
pubmed: 35189610
Med Phys. 2019 Nov;46(11):5144-5151
pubmed: 31529694
Korean J Anesthesiol. 2022 Feb;75(1):25-36
pubmed: 35124947
J Appl Clin Med Phys. 2020 Nov;21(11):195-204
pubmed: 33073454
Int J Radiat Oncol Biol Phys. 2020 Nov 15;108(4):1073-1081
pubmed: 32585334
Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):51-60
pubmed: 28816160
J Thorac Oncol. 2018 Oct;13(10):1508-1518
pubmed: 29883836
Int J Radiat Oncol Biol Phys. 2020 Jun 1;107(2):270-278
pubmed: 32105742
Radiother Oncol. 2017 Mar;122(3):416-422
pubmed: 28233564
J Clin Oncol. 2017 May 1;35(13):1387-1394
pubmed: 28113017
Radiother Oncol. 2017 Jun;123(3):370-375
pubmed: 28476219
Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):70-79
pubmed: 28816165
Radiother Oncol. 2021 Dec;165:119-125
pubmed: 34718053
Clin Lung Cancer. 2018 Mar;19(2):e241-e246
pubmed: 28941961
Lancet Oncol. 2015 Feb;16(2):187-99
pubmed: 25601342

Auteurs

Luuk H G van der Pol (LHG)

Department of Radiotherapy, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.

Sara L Hackett (SL)

Department of Radiotherapy, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.

Firdaus A A Mohamed Hoesein (FAAM)

Department of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands.

Louk M W Snoeren (LMW)

Department of Radiotherapy, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.

Jacqueline Pomp (J)

Department of Radiotherapy, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.

Bas W Raaymakers (BW)

Department of Radiotherapy, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.

Joost J C Verhoeff (JJC)

Department of Radiotherapy, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.

Martin F Fast (MF)

Department of Radiotherapy, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH